Detalhe da pesquisa
1.
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
N Engl J Med
; 390(6): 510-521, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324484
2.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 130-141, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891379
3.
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
N Engl J Med
; 385(24): 2219-2229, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34879448
4.
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 90(3): 485-493, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37852306
5.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
J Am Acad Dermatol
; 90(5): 986-993, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38253129
6.
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
J Am Acad Dermatol
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38556093
7.
Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials.
J Am Acad Dermatol
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38777187
8.
Cedirogant in adults with psoriasis: a phase 2, randomized, placebo-controlled clinical trial.
Clin Exp Dermatol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38699939
9.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451052
10.
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
J Allergy Clin Immunol
; 151(1): 172-181, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36195170
11.
Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
N Engl J Med
; 383(3): 229-239, 2020 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32668113
12.
Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
Rheumatology (Oxford)
; 62(2): 629-637, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35801915
13.
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
Rheumatology (Oxford)
; 62(6): 2113-2121, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282530
14.
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
Rheumatology (Oxford)
; 62(6): 2122-2129, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282537
15.
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Br J Dermatol
; 189(4): 392-399, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279795
16.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Br J Dermatol
; 189(5): 540-552, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488811
17.
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
Clin Exp Rheumatol
; 41(11): 2286-2297, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37404160
18.
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
J Am Acad Dermatol
; 88(5): 1008-1016, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36574595
19.
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
J Am Acad Dermatol
; 89(2): 274-282, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37019386
20.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36115523